Understanding how proteins interact in lung cancer to overcome drug resistance
Spatial protein-protein interaction networks in situ by multiplexed proximity ligation
['FUNDING_OTHER'] · GEORGIA INSTITUTE OF TECHNOLOGY · NIH-11141079
This work aims to understand why non-small cell lung cancer becomes resistant to a common treatment called osimertinib, by looking closely at how proteins interact within cancer cells.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGIA INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11141079 on ClinicalTrials.gov |
What this research studies
Patients with a specific type of non-small cell lung cancer (NSCLC) that has an EGFR gene change often receive a successful treatment called osimertinib. However, over time, the cancer usually becomes resistant to this medicine. We want to understand the exact changes that happen inside cancer cells when they become resistant to osimertinib. Our team is developing a new method to map out how proteins interact within these cancer cells and tissues, which could reveal new ways to make treatments work better and longer.
Who could benefit from this research
Good fit: This research is most relevant to patients with non-small cell lung cancer who have EGFR gene mutations and may experience resistance to targeted therapies like osimertinib.
Not a fit: Patients without non-small cell lung cancer or those whose cancer does not involve EGFR gene mutations would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new strategies and combination therapies to help patients with non-small cell lung cancer overcome drug resistance and improve their treatment outcomes.
How similar studies have performed: Pre-clinical studies have shown promise with combination therapies to delay or overcome osimertinib resistance, and a related method developed by this team has revealed insights into protein organization.
Where this research is happening
ATLANTA, UNITED STATES
- GEORGIA INSTITUTE OF TECHNOLOGY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COSKUN, AHMET F. — GEORGIA INSTITUTE OF TECHNOLOGY
- Study coordinator: COSKUN, AHMET F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Model